03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
02:23 , Jun 30, 2018 |  BioCentury  |  Product Development

Defining access potential - before it’s too late

We see it everywhere: confirmation bias. Innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. But confirmation bias is particularly problematic thanks...
19:31 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Sage postpartum depression candidate gets Priority Review

Sage Therapeutics Inc. (NASDAQ:SAGE) said FDA accepted and granted Priority Review to an NDA for brexanolone (SAGE-547) to treat postpartum depression (PPD). Its PDUFA date is Dec. 19. In November, the therapy met the primary endpoints...
16:24 , May 30, 2018 |  BC Extra  |  Company News

Sage's postpartum depression candidate gets Priority Review

Sage Therapeutics Inc. (NASDAQ:SAGE) said FDA accepted and granted Priority Review to an NDA for brexanolone (SAGE-547) to treat postpartum depression (PPD). Its PDUFA date is Dec. 19. In November, the therapy met the primary endpoints...
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:26 , Dec 7, 2017 |  BC Extra  |  Clinical News

Sage jumps on Phase II data for MDD candidate

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $64.37 (70%) to $156.27 on Thursday after reporting that SAGE-217 met the primary endpoint in a Phase II trial to treat moderate to severe major depressive disorder. Sage added over...
19:35 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Sage raises $300M follow-on

Sage Therapeutics Inc. (NASDAQ:SAGE) raised $300 million on Nov. 14 through the sale of 3.5 million shares at $85 in a follow-on underwritten by JPMorgan, Goldman Sachs, Morgan Stanley, Cowen and Leerink. On Nov. 9, Sage...
19:06 , Nov 15, 2017 |  BC Extra  |  Financial News

Sage raises $300M in follow-on

Sage Therapeutics Inc. (NASDAQ:SAGE) raised $300 million late Tuesday through the sale of 3.5 million shares at $85 in a follow-on underwritten by JPMorgan, Goldman Sachs, Morgan Stanley, Cowen and Leerink. On Nov. 9, Sage jumped...
21:23 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

Sage's brexanolone meets in Phase III trials for PPD

Sage Therapeutics Inc. (NASDAQ:SAGE) said brexanolone (formerly SAGE-547) met the primary endpoint in a pair of Phase III trials in the Hummingbird program to treat postpartum depression (PPD). Next year, the company plans to submit...